SEARCH

SEARCH BY CITATION

References

  • 1
    Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000; 356:194.
  • 2
    Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int 2001; 59:3.
  • 3
    Kreis H, Cisterne JM, Land W. Sirolimus in association with mycophenolate mofetil induction for prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69:1252.
  • 4
    Oberbauer R, Kreis H, Johnson RW et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study Group. Transplantation 2003; 76:364.
  • 5
    Denton MD, Galvanek EG, Singh A, et al. Membranous lupus nephritis in a renal allograft: response to mycophenolate mofetil therapy. Am J Transplant 2001; 1:288.
  • 6
    Nowack R, Birck R, van der Woude FJ et al. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 1997; 349:774.
  • 7
    Budde K, Fritsche L, Neumayer HH. Differing proteinuria control with cyclosporin and tacrolimus. Lancet 1997; 349:330.
  • 8
    Krämer BK, Schweda F. Differing proteinuria control with cyclosporin and tacrolimus. Lancet 1997; 349:953.
  • 9
    Floege J. Recurrent glomerulonephritis following renal transplantation: an update. Nephrol Dial Transplant 2003; 18:1260.
  • 10
    Dominguez J, Mahalati K, Kiberd B, et al. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 2000; 70:1244.
  • 11
    Hadaya K, Wissing M, Broders E, et al. Conversion to sirolimus after renal transplantation: High failure rate due to nephrotic proteinuria and other adverse events. J Am Soc Nephrol 2003; 14:185A.
  • 12
    Jim B, Doyle A, Bloom RD. Rapmycin is associated with worsening proteinuria in transplant patients with renal injury: a report of four cases. J Am Soc Nephrol 2003; 14:65A.
  • 13
    Daniel C, Ziswiler R, Frey B, et al. Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative. Exp Nephrol 2000; 8:52.
  • 14
    Day CJ, Cockwell P, Lipkin GW, et al. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 2002; 17:2011.
  • 15
    Gescuk BD, Davis JC. Novel theapeutic agents for systemic lupus erythematosus. Curr Opin Rheumatol 2002; 14:515.